Background Oral nirmatrelvir/ritonavir (Paxlovid) aims to avoid severe COVID‐19 in
asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and …

ABSTRACT Introduction On 31 July 2023, the United States Department of Health and
Human Services announced the formation of the Office of Long COVID Research and …

Nirmatrelvir is the main component of Paxlovid, an oral antiviral drug approved for the
treatment of COVID-19 caused by SARS-COV-2 infection. Nirmatrelvir targets the main …

The outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge
on public health systems. Despite the measures put in place to contain it, COVID-19 is likely …

Background: Scarce data exist that analyze the outcomes of hematological patients with
SARS-CoV-2 infection during the Omicron variant period who received treatment with …

Given the high pathogenicity and rapid mutation rates of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), it is imperative to sustain efforts in drug research and …

This study aimed to explore the effectiveness and safety of azvudine, nirmatrelvir/ritonavir,
and molnupiravir in adult patients with mild-to-moderate COVID-19. This retrospective cohort …

Since the outbreak of COVID‐19, many antiviral drugs have been used to treat infected
patients. Excessive drug concentrations may not only damage patients' organs, but also lead …

Modern directed antiviral COVID-19 therapy: results of multicenter clinical effectiveness and
safety study of fixed nirmatrelvir+ritonavir combination - Balykova - Pharmacy & Pharmacology …

В статье представлены данные открытого двухэтапного многоцентрового
исследования по оценке эффективности и безопасности комбинированного препарата …